Fad diets can work, but experts find no magic slimming bullet

January 13, 2014

Resolutions to lose weight are often made in January yet almost as frequently abandoned as heavy hopefuls find diets that demand fasting, virtually no carbs or liquid food shakes notoriously hard to stick to. But even "fad" diets can lead to a slimmer, lighter New Year for those whose resolve remains robust, according to doctors and nutritionists analysing them.

Gathering for a London conference to review evidence behind popular weight loss diets - at just the time of year when slimming ideas are in peak demand - specialists concluded that food fads such as the hunter-gatherer "Paleo" plan or the 5:2 diet can deliver. But it's hard work. "If it was easy, our species would have died out years ago. As humans we have a default to eat," said Gary Frost, a professor and chair of nutrition and dietetics at Imperial College London. The results of that default are looming large in a global "wave of obesity", he said. According to the World Health Organisation, worldwide obesity - defined as having a body mass index of more than 30 - has nearly doubled since 1980. The latest global figure is that in 2008, more than 1.4 billion adults were overweight.

WAVE OF OBESITY

According to the US Centers for Disease Control and Prevention, almost 36% of American adults are obese and almost 70% are either obese or overweight. In Britain, a government health study predicts 60% of men, 50% of women and 25% of children will be obese by 2050. Against this background, experts say the search for effective diets must always take account of how easy it is for people to understand and follow, and how likely they are to abide by its restrictions.

Michelle Harvie, a research dietician from the Genesis Prevention Centre at Britain's University Hospital of South Manchester, said that on this front, fasting diets - sometimes called intermittent diets - can be successful. "Energy restriction is difficult to maintain over the long term and people tend to find it easier to follow a diet with intermittent energy restriction," she said. She said that while a regular weight loss plan might require the dieter to take in 25% fewer calories, intermittent diets may suggest two days of a 75% calorie cut interspersed with five days of normal healthy eating. But the key to these diets - such as the 5:2 diet in which followers eat as little as 400 calories on two "fasting" days per week - is that dieters won't succeed if they "pig out" and eat whatever they want on non-fasting days.

Harvie's research shows those who succeed in losing weigh on these diets find the fasting days lead them to also have a lower food intake on normal days - leading to lower calorie intake overall.

HUNTING FOR FOOD

Mark Berry, head of plant biology and biochemistry at the consumer company Unilever's research and development unit, says there are also positive signs in data from studies of "Palaeolithic" or stone-age diets - plans designed to mimic the diet of pre-agricultural hunter-gatherers of that era. A sign of its current popularity is that "Paleo diet" was one of the most "Googled" terms of 2013.

The idea is based around foods that can be hunted, fished or foraged for - meat, seafood, eggs, nuts, seeds, fruits and vegetables. Berry said his research showed little impact on glucose response in the body in people eating a Palaeolithic diet, but did find a significant impact on hormones that signal satiety and tell the brain the eater is full. Alexandra Johnstone of the Rowett Institute of Nutrition and Health, who has been looking into high protein and low carbohydrate diets such as the Atkins diet, said these also had a significant impact on fullness feelings - giving them the potential to help dieters control appetite and lose weight. "The high satiety effects of increased protein in the diet seems to be a contributing factor to the success of high-protein, low-carbohydrate diets," she said.

Johnstone cited data showing the amount of weight lost on high-protein diets is around double that lost on a comparable low-fat diet at the six-month mark. But there is little difference in weight loss after one year, as dieters often lose momentum and their resolve to slim down fades. "There's no magic bullet," she said. Judy Buttriss, head of the British Nutrition Foundation, said the evidence for popular diets was clearly nuanced. While there are several that can be used as tools for effective weight loss and maintenance, she said "there's currently no evidence that one is any better than another in the long term".

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
May 26,2020

Tedros Adhanom Ghebreyesus, the World Health Organisation's (WHO) Director-General, said that a clinical trial of hydroxychloroquine (HCQ) on COVID-19 patients has come to "a temporary pause", while the safety data of the the anti-malaria drug was being reviewed.

According to the WHO chief, The Lancet medical journal on May 22 had published an observational study on HCQ and chloroquine and its effects on COVID-19 patients that have been hospitalized, reports Xinhua news agency.

The authors of the study reported that among patients receiving the drug, when used alone or with a macrolide, they estimated a higher mortality rate.

"The Executive Group of the Solidarity Trial, representing 10 of the participating countries, met on Saturday (May 23) and has agreed to review a comprehensive analysis and critical appraisal of all evidence available globally," Tedros said in a virtual press conference on Monday.

The review will consider data collected so far in the Solidarity Trial and in particular robust randomized available data, to adequately evaluate the potential benefits and harms from this drug, he said.

"The Executive Group has implemented a temporary pause of the HCQ arm within the Solidarity Trial while the safety data is reviewed by the Data Safety Monitoring Board. The other arms of the trial are continuing," Tedros added.

WHO initiated the Solidarity Trial, a plan to evaluate the safety and efficacy of four drugs and drug combinations against COVID-19 more than two months ago, which include HCQ.

According to the WHO, over 400 hospitals in 35 countries are actively recruiting patients and nearly 3,500 patients have been enrolled from 17 countries under the Solidarity Trial.

Tedros added that the safety concern over the drug related only to the use of HCQ and chloroquine in COVID-19, and "these drugs are accepted as generally safe for use in patients with autoimmune diseases or malaria".

"WHO will provide further updates as we know more," he added.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
June 4,2020

The World Health Organisation on Wednesday said that anti-malarial drug hydroxychloroquine (HCQ) will return to the solidarity trial for the potential treatment of coronavirus disease.

At a press conference in the WHO headquarters in Geneva, Director General Tedros Adhanom Ghebreyesus said: "On the basis of the available mortality data, the members of the committee recommended that there are no reasons to modify the trial protocol. The Executive Group received this recommendation and endorsed continuation of all arms of the solidarity trial, including hydroxychloroquine."

The world health body had temporarily suspended the usage of HCQ from the solidarity trial for coronavirus treatment on May 25 soon after a study published in one of the most reliable medical journals, which had suggested that the drug could cause more fatalities among COVID-19 patients.

However, the WHO chief said that the decision was taken as a precaution while the safety data was reviewed.

Ghebreyesus also said that the Data Safety and Monitoring Committee will continue to closely monitor the safety of all therapeutics being tested in the solidarity trial.

"So far, more than 3,500 patients have been recruited in 35 countries. WHO is committed to accelerating the development of effective therapeutics, vaccines and diagnostics as part of our commitment to serving the world with science, solutions and solidarity," he said.

Soon after HCQ was suspended from the trial, the Indian government had said that the antimalarial drug has been known for its benefits for a long time and its usage will be continued on the frontline workers, including police and healthcare professionals, as prophylaxis. The government had also said that studies were being conducted and the drug would be included in the clinical trial also for the treatment of coronavirus disease.

US President Donald Trump also had strongly advocated the use of HCQ and called it a "game-changer". He went to the extent of saying that he had taken the medicine.

Launched by WHO and partners, solidarity trial is an international clinical trial to find an effective treatment for COVID-19, including drugs to slow the progression of the disease or improve survival. The trial, which enrols patients from different countries, "will compare four treatment options against standard of care to assess their relative effectiveness against COVID-19", said WHO. 

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
February 4,2020

Boston, Feb 4: Practising yoga may increase levels of a messenger molecule involved in regulating brain activity, and completing one yoga class per week may maintain elevated levels of this chemical, according to a study which may lead to better ways of mitigating depressive symptoms.

The study, published in the Journal of Alternative and Complementary Medicine, assessed a group of 30 clinically depressed patients who were randomly divided into two groups.

According to the researchers, including those from Boston University in the US, both groups engaged in coherent breathing, and Iyengar yoga -- a form of hatha yoga, developed by B. K. S. Iyengar, emphasising on detail, precision, and alignment in the performance of yoga postures.

The only difference between the groups, the scientists said, was the number of 90 minute yoga sessions, and home sessions in which each group participated.

Over three months, they said, the high-dose group (HDG) was assigned three sessions per week, while the low-intensity group (LIG) engaged in two sessions per week.

The participants underwent magnetic resonance imaging (MRI) scans of their brain before the first and after the last yoga session, and also completed a clinical depression scale to monitor their symptoms, the study noted.

Results of the study revealed that both groups had improvement in depressive symptoms after three months.

Their MRI analysis showed that levels of the brain messenger molecule GABA were elevated after three months of yoga, as compared to the levels before starting yoga.

According to the study, this increase was found for approximately four days after the last yoga session, but the rise was no longer observed after about eight days.

"The study suggests that the associated increase in GABA levels after a yoga session are 'time-limited' similar to that of pharmacologic treatments such that completing one session of yoga per week may maintain elevated levels of GABA," explained study co-author Chris Streeter from Boston University.

Providing evidence-based data may help in getting more individuals to try yoga as a strategy for improving their health and well-being, the scientists said.

"A unique strength of this study is that pairing the yoga intervention with brain imaging provides important neurobiological insight as to the 'how' yoga may help to alleviate depression and anxiety," said study co-author Marisa Silveri from Harvard University.

In this study, we found that an important neurochemical, GABA, which is related to mood, anxiety, and sleep, is significantly increased in association with a yoga intervention," Silveri said.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.